United Therapeutics Corp (UTHR)
258.74
+0.63
(+0.24%)
USD |
NASDAQ |
May 03, 11:31
United Therapeutics Cash from Investing (Quarterly): 735.30M for March 31, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 735.30M |
December 31, 2023 | 42.10M |
September 30, 2023 | -313.40M |
June 30, 2023 | -227.20M |
March 31, 2023 | -221.10M |
December 31, 2022 | -189.30M |
September 30, 2022 | -94.00M |
June 30, 2022 | -169.00M |
March 31, 2022 | -359.20M |
December 31, 2021 | -195.80M |
September 30, 2021 | -235.90M |
June 30, 2021 | -48.90M |
March 31, 2021 | -6.30M |
December 31, 2020 | -63.80M |
September 30, 2020 | -271.70M |
June 30, 2020 | -375.40M |
March 31, 2020 | -27.60M |
December 31, 2019 | 66.20M |
September 30, 2019 | -298.70M |
June 30, 2019 | -42.60M |
March 31, 2019 | -60.30M |
December 31, 2018 | -72.20M |
September 30, 2018 | -329.90M |
June 30, 2018 | -359.80M |
March 31, 2018 | -58.70M |
Date | Value |
---|---|
December 31, 2017 | -278.40M |
September 30, 2017 | -200.20M |
June 30, 2017 | -191.40M |
March 31, 2017 | -165.60M |
December 31, 2016 | 8.50M |
September 30, 2016 | 20.10M |
June 30, 2016 | 7.70M |
March 31, 2016 | 12.00M |
December 31, 2015 | 56.50M |
September 30, 2015 | 347.60M |
June 30, 2015 | 31.10M |
March 31, 2015 | 68.40M |
December 31, 2014 | 51.99M |
September 30, 2014 | 97.95M |
June 30, 2014 | 82.18M |
March 31, 2014 | 106.38M |
December 31, 2013 | -156.35M |
September 30, 2013 | -175.82M |
June 30, 2013 | 26.57M |
March 31, 2013 | 10.64M |
December 31, 2012 | -164.70M |
September 30, 2012 | 47.61M |
June 30, 2012 | -0.287M |
March 31, 2012 | -45.99M |
December 31, 2011 | 16.18M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-375.40M
Minimum
Jun 2020
735.30M
Maximum
Mar 2024
-114.82M
Average
-179.15M
Median
Cash from Investing (Quarterly) Benchmarks
Liquidia Corp | -0.206M |
Esperion Therapeutics Inc | 0.00 |
Vertex Pharmaceuticals Inc | -886.50M |
Heron Therapeutics Inc | -8.836M |
Aldeyra Therapeutics Inc | 0.00 |
Cash from Investing (Quarterly) Related Metrics
Cash from Operations (Quarterly) | 376.50M |
Cash from Financing (Quarterly) | -1.068B |
Free Cash Flow | 752.40M |
Free Cash Flow Per Share (Quarterly) | 6.807 |
Free Cash Flow to Equity (Quarterly) | 438.30M |
Free Cash Flow to Firm (Quarterly) | 338.30M |
Free Cash Flow Yield | 5.85% |